[go: up one dir, main page]

CA2491129A1 - Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques - Google Patents

Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques Download PDF

Info

Publication number
CA2491129A1
CA2491129A1 CA002491129A CA2491129A CA2491129A1 CA 2491129 A1 CA2491129 A1 CA 2491129A1 CA 002491129 A CA002491129 A CA 002491129A CA 2491129 A CA2491129 A CA 2491129A CA 2491129 A1 CA2491129 A1 CA 2491129A1
Authority
CA
Canada
Prior art keywords
antibody
aerosol
subject
ratio
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491129A
Other languages
English (en)
Inventor
Richard S. Blumberg
Wayne I. Lencer
Neil E. Simister
Alan J. Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Bioverativ Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2491129A1 publication Critical patent/CA2491129A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La pr~sente invention concerne des proc~d~s et des produits destin~s ~ l'administration syst~mique trans~pith~liale d'agents th~rapeutiques. Plus particuli­rement, la pr~sente invention concerne des proc~d~s et des compositions permettant l'administration syst~mique d'agents th~rapeutiques par introduction d'un a~rosol contenant des anticorps ou des conjugu~s d'un agent th~rapeutique avec un partenaire de liaison FcRn dans l'~pith~lium des voies a~riennes centrales du poumon. Les proc~d~s et les dispositifs d~crits dans cette invention peuvent s'adapter ~ une large gamme d'agents th~rapeutiques parmi lesquels les prot~ines et les polypeptides, les acides nucl~iques, les m~dicaments, etc. Ces proc~d~s et ces produits pr~sentent l'avantage de ne pas n~cessiter d'introduction en profondeur dans le poumon pour permettre l'administration syst~mique.
CA002491129A 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques Abandoned CA2491129A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US02/21335 2002-07-03
PCT/US2002/021335 WO2003077834A2 (fr) 2002-03-15 2002-07-03 Apport par les voies aeriennes centrales pour l'administration systemique de medicaments
PCT/US2003/014428 WO2004004798A2 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Publications (1)

Publication Number Publication Date
CA2491129A1 true CA2491129A1 (fr) 2004-01-15

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491129A Abandoned CA2491129A1 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Country Status (5)

Country Link
EP (1) EP1539246A4 (fr)
JP (1) JP2006513139A (fr)
AU (1) AU2003232081B2 (fr)
CA (1) CA2491129A1 (fr)
WO (1) WO2004004798A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2005207960A1 (en) 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
EP2053062A1 (fr) 2004-03-24 2009-04-29 Xencor, Inc. Variantes d'immunoglobine en dehors de la région Fc
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007008943A2 (fr) 2005-07-08 2007-01-18 Xencor, Inc. Proteines optimisees qui ciblent la molecule ep-cam
EP1931709B1 (fr) 2005-10-03 2016-12-07 Xencor, Inc. Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP3392273A1 (fr) 2007-05-30 2018-10-24 Xencor, Inc. Procédés et compositions pour inhiber des cellules exprimant cd32b
CA2693771A1 (fr) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Compositions et methodes d'administration pulmonaire d'un inhibiteur du tnf.alpha.
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
JP5314033B2 (ja) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
EP3190128B1 (fr) 2008-09-17 2018-11-14 Xencor, Inc. Compositions et méthodes de traitement de troubles induits par ige
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
WO2011091078A2 (fr) 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
ES2902689T3 (es) 2014-04-03 2022-03-29 Csl Behring Ag Nebulización de inmunoglobulina
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
JP2019503341A (ja) * 2015-11-16 2019-02-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
JP2024534053A (ja) * 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
EP1658772A3 (fr) * 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Transport épithélial spécifique de récepteurs d'immunogènes
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
EP1273306A4 (fr) * 2000-03-31 2005-06-22 Kirin Brewery Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
TWI327600B (en) * 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
CA2479212A1 (fr) * 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Apport par les voies aeriennes centrales pour l'administration systemique de medicaments

Also Published As

Publication number Publication date
WO2004004798A2 (fr) 2004-01-15
AU2003232081B2 (en) 2009-02-05
WO2004004798A3 (fr) 2004-10-14
EP1539246A2 (fr) 2005-06-15
EP1539246A4 (fr) 2007-05-16
JP2006513139A (ja) 2006-04-20
AU2003232081A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
AU2003232081B2 (en) Central airway administration for systemic delivery of therapeutics
US20060140907A1 (en) Central airway administration for systemic delivery of therapeutics
US20040063912A1 (en) Central airway administration for systemic delivery of therapeutics
US7060274B2 (en) Receptor specific transepithelial transport of therapeutics
CA2297101C (fr) Transport trans-epithelial d'agents therapeutiques specifique de recepteur
AU2005311101B2 (en) Anti-IL-IRI single domain antibodies and therapeutic uses
KR20160062760A (ko) 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
WO2004062603A2 (fr) Methodes de traitement de maladies pulmonaires
CA2631981A1 (fr) Procedes et compositions d'apport sans aiguille de partenaires de liaison
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
WO2022191158A1 (fr) Procédé de production d'une protéine de fusion anticorps/enzyme lysosomale
WO2016079276A1 (fr) Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
TW202405018A (zh) Ｃｄ７３抗體雞尾酒療法
CN118043064A (zh) 可活化细胞因子构建体及组合方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead